Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
Kircik LH, Alonso-Llamazares J, Bhatia N, Bukhalo M, Devani AR, Draelos ZD, DuBois J, Gooderham MJ, Kempers SE, Lain E, Lee M, Moore A, Murrell DF, Papp KA, Pariser DM, Sinclair R, Zirwas M, Burnett P, Higham RC, Krupa D, Berk DR. Kircik LH, et al. Among authors: draelos zd. Br J Dermatol. 2023 Sep 15;189(4):392-399. doi: 10.1093/bjd/ljad182. Br J Dermatol. 2023. PMID: 37279795 Clinical Trial.
Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
Feldman SR, Matheson R, Bruce S, Grande K, Markowitz O, Kempers S, Brundage T, Wyres M; U0267-301 & 302 Study Investigators. Feldman SR, et al. Am J Clin Dermatol. 2012 Aug 1;13(4):261-71. doi: 10.2165/11630710-000000000-00000. Am J Clin Dermatol. 2012. PMID: 22587791 Clinical Trial.
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Langley RG, et al. N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9. N Engl J Med. 2014. PMID: 25007392 Free article. Clinical Trial.
WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials.
Stein-Gold L, Kircik LH, Draelos ZD, Werschler P, DuBois J, Lain E, Baumann L, Goldberg DJ, Kaufman J, Tanghetti EA, Alvandi N, Weng E, Berk DR, Ahluwalia G. Stein-Gold L, et al. Among authors: draelos zd. J Am Acad Dermatol. 2018 Jan 31:S0190-9622(18)30147-6. doi: 10.1016/j.jaad.2018.01.028. Online ahead of print. J Am Acad Dermatol. 2018. PMID: 29409915 Free article. Retracted.
Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind, placebo-controlled, phase 3 studies (A-101-SEBK-301/302).
Baumann LS, Blauvelt A, Draelos ZD, Kempers SE, Lupo MP, Schlessinger J, Smith SR, Wilson DC, Bradshaw M, Estes E, Shanler SD. Baumann LS, et al. Among authors: draelos zd. J Am Acad Dermatol. 2018 Nov;79(5):869-877. doi: 10.1016/j.jaad.2018.05.044. Epub 2018 Jun 1. J Am Acad Dermatol. 2018. PMID: 29864467 Free article. Clinical Trial.
Polymeric Emulsion Technology Applied to Tretinoin.
Kircik LH, Draelos ZD, Berson DS. Kircik LH, et al. Among authors: draelos zd. J Drugs Dermatol. 2019 Apr 1;18(4):s148-154. J Drugs Dermatol. 2019. PMID: 31017754 No abstract available.
285 results